Garivulimab - CAS 2342597-81-1

Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1, thereby selectively inhibiting the PD-L1/PD-1 interaction, which confers its antitumor activity [1].

PD-1/PD-L1, Apoptosis

Apoptosis, Cell Cycle/Checkpoint, Immunology/Inflammation

2342515

-20°C

Ice Packs

Inhibitory Antibodies